Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.45 |
| ▸ | VEGFA | P15692 | 4/20 | 0.45 |
| ▸ | FLT1 | P17948 | 4/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452969 | 1.00 | GAA (0.51) | GAARAB9ASMN1; SMN2EGLN1VEGFA | |
| SCHEMBL24257697 | 0.90 | EGLN1 (0.50) | GAARAB9AEGLN1 | |
| SCHEMBL24257497 | 0.89 | EGLN1 (0.57) | SMN1; SMN2EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL24257568 | 0.87 | EGLN1 (0.58) | EGLN1VEGFAFLT1EGLN3PPID | |
| SCHEMBL24257693 | 0.87 | EGLN1 (0.51) | EGLN1VEGFAFLT1EGLN3ALDH1A1 | |
| SCHEMBL30452725 | 0.85 | EGLN1 (0.50) | GAARAB9ASMN1; SMN2EGLN1VEGFA | |
| SCHEMBL24257817 | 0.85 | EGLN1 (0.50) | GAARAB9ASMN1; SMN2EGLN1VEGFA | |
| SCHEMBL24257686 | 0.84 | GAA (0.48) | GAARAB9ASMN1; SMN2EGLN1ALDH1A1 | |
| SCHEMBL30452826 | 0.84 | GAA (0.48) | GAARAB9ASMN1; SMN2EGLN1ALDH1A1 | |
| SCHEMBL24257545 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2EGLN1VEGFAFLT1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | GAA 3783/4885RAB9A 739/4885SMN1; SMN2 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.